Authors:
ESCOTT KJ
MCMILLAN SJ
BIRRELL M
WEBBER SE
SOUNESS JE
MASLEN C
TEMPLE R
IQBAL S
MARIUCCI M
ROSE J
GEIGER LE
THURAIRATNAM S
BOWER S
ALDOUS D
SARGENT CA
Citation: Kj. Escott et al., PHARMACOLOGICAL PROFILING OF PHOSPHODIESTERASE-4 (PDE4) INHIBITORS AND ANALYSIS OF THE THERAPEUTIC RATIO IN RATS AND DOGS, British Journal of Pharmacology, 123, 1998, pp. 40-40
Citation: R. Temple, THE CHALLENGE OF REGULATING DEVELOPMENT AND APPROVAL DRUGS WITH PLEIOTROPIC ACTION IN CARDIOVASCULAR-DISEASE, The American journal of cardiology, 81(8A), 1998, pp. 5-8
Citation: C. Marwick et al., CLINICAL-TRIAL INVESTIGATORS TALK ABOUT GETTING THE DATA - DISCUSSION, JAMA, the journal of the American Medical Association, 277(23), 1997, pp. 1833-1836
Citation: Ga. Burkhart et al., TEMPORAL DECLINE IN FILLING PRESCRIPTIONS FOR TERFENADINE CLOSELY IN TIME WITH THOSE FOR EITHER KETOCONAZOLE OR ERYTHROMYCIN, Clinical pharmacology and therapeutics, 61(1), 1997, pp. 93-96
Authors:
BLACK HR
COHEN JD
KAPLAN NM
FERDINAND KC
CHOBANIAN AV
DUSTAN HP
GIFFORD RW
MOSER M
SHEPS SG
AGODOA L
AUGUST PA
BAKRIS GL
BURT V
BUSSE W
CARTER BL
CHESLEY FD
CLEEMAN J
COHN JN
CREGLER LL
CRESPO C
CUSHMAN WC
CUTLER J
DARROW MD
DEQUATTRO VL
DEVEREUX RB
DWORKIN LD
ELLIOTT WJ
EPSTEIN M
FALKNER B
FERRARIO CM
FLACK JM
FRISHMAN W
FROHLICH ED
GREEN LA
GRIMM RH
HAGBERG JM
HALL WD
HANDLER J
HAVAS S
HILL MN
HORAN MJ
HSUEH WA
HYMAN BN
IZZO JL
JAMERSON K
KILEY JP
KOCHAR MS
KOLASA KM
KRAKOFF LR
LEVY D
LINDHEIMER MD
LUEPKER RV
MALONE MEL
MASSIE B
MATERSON BJ
MERCHANT J
MESSERLI FH
MILLER NH
MOORE MA
MUSTONEALEXANDER L
OPARIL S
PERRY HM
PICKERING TG
PRATT JH
RAM CVS
RANDALL OS
REED JW
ROBERTS RW
ROCCELLA EJ
ROGUS SD
SAUNDERS E
SCHRON E
SCHWARTZ G
SIBAI BM
SNYDER D
SOWERS JR
STAMLER J
TEMPLE R
TEXTOR S
THOM T
VIDT DG
WEBER M
WEINBERGER MH
WEINSHILBOUM R
WHELTON PK
WHISNANT JP
WIEBERS DO
WINSTON MC
WRIGHT JT
LENFANT C
CASSER L
COLMAN PJ
EDWARDS T
FEELEY DM
GAJEWSKI J
LEVINE D
MANGER W
MARSHALL EC
NICKEY WA
ROBERT RW
SECREST BG
SINGER EH
WHISNANT JP
WILSON GJ
YOUNG JM
BACHMAN JW
CAMPESE VM
CARR AA
HAND M
HOLDEN DC
JAMIESON MJ
JULIUS S
MENSAH GA
PRISANT M
SULLIVAN JM
WILSON DJ
MOROSCO G
ANDERSON DE
WAUGH D
Citation: Hr. Black et al., THE 6TH REPORT OF THE ,-EVALUATION,-AND-TREATMENT-OF-HIGH-BLOOD-PRESSURE, Archives of internal medicine, 157(21), 1997, pp. 2413-2446
Citation: R. Temple et P. Obrien, WHY WOULD ANYONE HAVE EXPECTED ANYTHING ELSE - CHARACTERISTICS OF MATERIALS DISTRIBUTED BY DRUG COMPANIES - 4 POINTS-OF-VIEW, Journal of general internal medicine, 11(10), 1996, pp. 640-641
Authors:
KESSLER DA
HASS AE
FEIDEN KL
LUMPKIN M
TEMPLE R
Citation: Da. Kessler et al., APPROVAL OF NEW DRUGS IN THE UNITED-STATES - COMPARISON WITH THE UNITED-KINGDOM, GERMANY, AND JAPAN, JAMA, the journal of the American Medical Association, 276(22), 1996, pp. 1826-1831
Authors:
MERKATZ RB
TEMPLE R
SOBEL S
FEIDEN K
KESSLER DA
Citation: Rb. Merkatz et al., WOMEN IN CLINICAL-TRIALS OF NEW DRUGS - A CHANGE IN FOOD-AND-DRUG-ADMINISTRATION POLICY, The New England journal of medicine, 329(4), 1993, pp. 292-296
Citation: Tg. Wilson et al., THE RESULTS OF EFFORTS TO IMPROVE COMPLIANCE WITH SUPPORTIVE PERIODONTAL TREATMENT IN A PRIVATE-PRACTICE, Journal of periodontology, 64(4), 1993, pp. 311-314
Citation: Da. Drossman et al., WORK ABSENTEEISM, DISABILITY AND HEALTH-CARE USE IN A NATIONAL SAMPLEOF PERSONS WITH FUNCTIONAL GI DISORDERS, Gastroenterology, 104(4), 1993, pp. 499-499